Venus Remedies Limited

NSE:VENUSREM.NS

309.9 (INR) • At close November 4, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 6,014.55,555.15,986.4975,481.2353,366.323,174.1593,694.5663,962.6044,149.3944,634.6155,363.2354,679.4264,098.3843,640.743,146.1162,695.4622,183.5391,464.809
Cost of Revenue 4,526.33,309.93,982.3573,519.5781,848.8951,924.3062,139.472,364.5652,467.9522,770.8893,079.9242,692.2772,259.1432,148.3131,925.391,690.4941,380.075932.742
Gross Profit 1,488.22,245.22,004.141,961.6571,517.4251,249.8531,555.0961,598.0391,681.4421,863.7262,283.3111,987.1491,839.2411,492.4271,220.7261,004.967803.464532.066
Gross Profit Ratio 0.2470.4040.3350.3580.4510.3940.4210.4030.4050.4020.4260.4250.4490.410.3880.3730.3680.363
Reseach & Development Expenses 158.4228.9230.299118.699142.523146.53306.38585.679107.001120.83166.566160.2630128.355110.78477.40951.55130.715
General & Administrative Expenses 998.2115.55491.076111.636104.64356.72548.8644.0132.59341.11732.86424.648560.155116.558100.933105.92178.87765.316
Selling & Marketing Expenses 132.535801487.094660.295417.612314.066386.805325.122394.696440.087395.492289.3770342.751267.114184.995127.25766.822
SG&A 998.2801578.17771.931522.255370.791435.665369.132427.289481.204428.356314.025560.155459.309368.047290.916206.134132.138
Other Expenses 115.8103.210.775130.13123.72522.62118.86518.44515.2712.2440.9231.704000000
Operating Expenses 1,156.61,966.21,718.3361,776.6481,429.3611,264.3991,497.5041,233.1291,285.5971,429.9591,333.9471,115.7751,055.865777.455616.241434.654322.443203.461
Operating Income 331.6283.889290.429315.14111.788-11.54362.93742.05135.07126.48690.79626.722783.429714.972604.486570.313481.021328.606
Operating Income Ratio 0.0550.0510.0490.0570.033-0.0040.0170.0110.0080.0060.1290.1340.1910.1960.1920.2120.220.224
Total Other Income Expenses Net 114.895.41573.652170.394-192.142-285.715-338.253-0.0010.002-0.0020.0011.638-274.904-188.642-140.701-93.547-47.682-28.088
Income Before Tax 446.4379.3364.081485.534-80.355-297.258-275.31642.0535.07326.478690.791628.36508.525526.33463.785476.767433.34300.518
Income Before Tax Ratio 0.0740.0680.0610.089-0.024-0.094-0.0750.0110.0080.0060.1290.1340.1240.1450.1470.1770.1980.205
Income Tax Expense 161.5113.6-43.161-132.1219.639-11.531.602-37.04118.084-25.12947.82255.26837.75364.14968.19637.25175.24446.682
Net Income 284.9265.7407.242617.654-99.993-285.747-306.91879.09116.98851.607642.968573.093470.772462.181395.589439.516358.095253.836
Net Income Ratio 0.0470.0480.0680.113-0.03-0.09-0.0830.020.0040.0110.120.1220.1150.1270.1260.1630.1640.173
EPS 21.3119.8730.4750.04-8.1-23.16-24.87-14.881.484.5157.1758.851.2250.6346.6951.9942.3630.19
EPS Diluted 21.3119.8730.4750.04-8.1-23.16-24.87-14.881.484.5157.1758.851.2250.6346.6951.9942.3630.19
EBITDA 596705.2701.399673.978513.117353.302401.264804.405778.085802.0031,343.0331,175.4111,035.629906.01741.896636.641545.78369.213
EBITDA Ratio 0.0990.1270.1170.1230.1520.1110.1090.2030.1880.1730.250.2510.2530.2490.2360.2360.250.252